Relay Therapeutics is trading 12.11% up now at $22.50 after recent bullish analyst commentary and clinical progress supporting zovegalisib’s development outlook.
- Citizens raised its price target to $26 from $21 on August 10, citing pooled data from 109 patients and increased confidence in the Phase 3 readout.
- No new August 13 company announcement was found, so the pre-market jump may reflect a delayed reaction to the upgrade and biotech momentum.